19181-77-2

Basic information

• Product Name: 8-Quinazolinecarboxylic acid, 3,4-dihydro-4-oxo-
• Synonyms: 8-Quinazolinecarboxylic acid, 3,4-dihydro-4-oxo-;3,4-Dihydro-4-oxo-8-quinazolinecarboxylic acid;4-oxo-3,4-dihydroquinazoline-8-carboxylic acid;4-oxo-1H-quinazoline-8-carboxylic acid;3,4-DIHYDRO-4-OXO-8-QUINAZOLINECARBOXYLIC ACID(WXG01642)
• CAS NO: 19181-77-2
• Molecular Formula: C₉H₆N₂O₃
• Molecular Weight: 190.15554
• Mol File: 19181-77-2.mol
• Article Data: 7

Chemical Properties

• Melting Point: 310-315 °C (decomp)
• Boiling Point: 428.9±47.0 °C(Predicted)
• Appearance: /
• Density: 1.56±0.1 g/cm3(Predicted)
• PKA: 3.23±0.20(Predicted)
• CAS DataBase Reference: 8-Quinazolinecarboxylic acid, 3,4-dihydro-4-oxo-(CAS DataBase Reference)
• NIST Chemistry Reference: 8-Quinazolinecarboxylic acid, 3,4-dihydro-4-oxo-(19181-77-2)
• EPA Substance Registry System: 8-Quinazolinecarboxylic acid, 3,4-dihydro-4-oxo-(19181-77-2)

Safety Data

• Hazardous Substances Data: 19181-77-2(Hazardous Substances Data)

Usage

General Description

8-Quinazolinecarboxylic acid, 3,4-dihydro-4-oxo- is a chemical compound that belongs to the quinazoline class of organic molecules. It is a heterocyclic compound containing a quinazoline ring and a carboxylic acid functional group. This chemical has potential utility in medicinal and pharmaceutical applications, particularly in the development of new drugs and therapies. Its structure and properties make it an interesting target for research and development, as it has the potential to exhibit biological activity that could be beneficial for various medical purposes. The compound's 3,4-dihydro-4-oxo- moiety contributes to its reactivity and potential pharmacological properties, and it may be studied further for its potential uses in the field of medicine.

Upstream product

• 39622-79-2 2-aminoisophthalic acid 
• 3473-63-0 formamidine acetic acid 
• 77287-34-4 formamide 
• 50-00-0 formaldehyd 
• 1379546-43-6 4-oxo-4H-3,1-benzoxazine-8-carboxylic acid 

Downstream Products

• 1379545-91-1 4-[(S)-2-azetidin-1-yl-1-(3-fluorophenyl)-ethylamino]-quinazoline-8-carboxamide 
• 1240474-61-6 4-((S)-2-dimethylamino-1-phenyl-ethylamino)-quinazoline-8-carboxamide 
• 1240476-05-4 4-((S)-2-cyclopropylamino-1-phenyl-ethylamino)-quinazoline-8-carboxamide 
• 1240477-26-2 4-(3,4,5-trifluoro-benzylamino)-quinazoline-8-carboxamide 
• 1240476-18-9 4-(3,4-difluoro-benzylamino)-quinazoline-8-carboxamide 
• 1240472-53-0 4-(3,5-difluoro-benzylamino)-quinazoline-8-carboxamide 
• 1240473-65-7 4-(2,4-difluoro-benzylamino)-quinazoline-8-carboxamide 

Relevant articles and documents

Identification of Clinical Candidate M2698, a Dual p70S6K and Akt Inhibitor, for Treatment of PAM Pathway-Altered Cancers

Herein, we report the discovery of a novel class of quinazoline carboxamides as dual p70S6k/Akt inhibitors for the treatment of tumors driven by alterations to the PI3K/Akt/mTOR (PAM) pathway. Through the screening of in-house proprietary kinase library, 4-benzylamino-quinazoline-8-carboxylic acid amide 1 stood out, with sub-micromolar p70S6k biochemical activity, as the starting point for a structurally enabled p70S6K/Akt dual inhibitor program that led to the discovery of M2698, a dual p70S6k/Akt inhibitor. M2698 is kinase selective, possesses favorable physical, chemical, and DMPK profiles, is orally available and well tolerated, and displayed tumor control in multiple in vivo studies of PAM pathway-driven tumors.

QUINAZOLINE CARBOXAMIDE AZETIDINES

The invention provides novel quinazoline carboxamide azetidine compounds according to Formula (I) and use for the treatment of hyperproliferative diseases, such as cancer.

RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF

Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.